Legal
Swiss pharma giant Novartis has found itself at the center of a legal battle that could determine if the company engaged in a research project that was a kickback in disguise.
Federal corporate tax cuts that were framed as a way to give a boost to employment across the United States have been more beneficial to companies and shareholders than the average worker or consumer, a new report issued by the advocacy group Americans for Tax Fairness shows.
As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. Let us know which topics you want to hear more about.
Yesterday, shareholders filed for a class action lawsuit against Tesaro in Delaware federal court, alleging that the merger is based on misleading financial analyses filed with the U.S. Securities and Exchange Commission (SEC).
A mechanism expected to overcome checkpoint blockade in T cells
Initial results from ongoing Phase 1 study for mesothelin-targeted CAR T support activity and safety in patients with advanced solid tumors
Opposes IPI as Proposed Because of Serious Concerns About Patient Impact and Legality but Working on Alternatives; Releases Research Analysis on Myth of Physician Incentives in Part B System
Management to Host Conference Call at 8:30 a.m. ET/5:30 a.m. PT
As news continues about Johnson & Johnson’s talcum powder containing carcinogenic asbestos, more than 100 drug inspectors in India are seizing samples, characterized The Times of India. The company, however, downplays that description, suggesting that the samples are fairly routine.
A Reuters analysis of company documents reveals that Johnson & Johnson knew about levels of asbestos contamination in its talc products, but did not report it to the FDA.
PRESS RELEASES